Spotlight on Pathology

Roy S. Herbst, MD, PhD
Credits: 0.75 CME / MOC
On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠
Roy S. Herbst, MD, PhD
RMEI Medical Education, LLC

On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Pathology Presentations

Jacob Sands, MD
1.0 CME / CC
Vindico Medical Education
TROP2 in Non-Small Cell Lung Cancer: A Novel Therapeutic Target

TROP2 in Non-Small Cell Lung Cancer: A Novel Therapeutic Target

Start

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABPath CC Point(s)
Released: March 31, 2022
Expires: March 30, 2023
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other health care professionals involved in the management of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the role of trophoblast cell surface antigen 2 (TROP2) in tumor biology as well as its implications as a cancer biomarker.
  • Describe how novel antibody drug conjugates exploit TROP2 as an anticancer therapy.
  • Examine current unmet needs for patients with NSCLC without actionable mutations.
  • Assess the latest clinical safety and efficacy regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior treatment.

Activity Description

For patients with non-small cell lung cancer (NSCLC) who do not have actionable genomic alterations, programmed death ligand 1 immunotherapy, with or without platinum-based chemotherapy, is the standard of care. These regimens have demonstrated clear clinical benefit, yet 40% to 60% of patients do not respond to these initial therapies, or eventually experience disease progression. Options are limited for these patients, but novel therapies, such as antibody drug conjugates that target trophoblast cell surface antigen 2 (TROP2), are currently under clinical investigation. TROP2 is expressed in approximately 70% of NSCLC tumors, and expression has been associated with poor outcomes. In this continuing medical education activity, experts in the field will review current unmet needs for patients with NSCLC without actionable mutations, discuss the role of TROP2 in tumor biology and its implications as a cancer biomarker, and assess the most recent clinical safety and efficacy data regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior therapies.

Topic

  • Introduction
  • TROP2: Role in Tumor Biology and Implications for Biomarker (Jacob Sands, MD)
  • Second-line Therapy for Patients With Non-Small Cell Lung Cancer: Unmet Needs (Benjamin P. Levy, MD)
  • Advances in TROP2-Targeted Therapies for Patients With Non-Small Cell Lung Cancer (Rebecca Heist, MD)
  • Conclusion by Activity Chair

Activity Chair

Jacob Sands, MD
Physician, Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Boston, MA

Disclosure:
Consultant: AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Takeda

Faculty

Rebecca Heist, MD
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA

Disclosure:
Consultant: AbbVie, Daichii Sankyo, EMD Serono, Novartis
Independent Research Contractor (paid to institution): AbbVie, Agios, Corvus, Daichii Sankyo, Exelixis, Lilly, Mirati, Novartis, Turning Point


Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Washington, DC

Disclosure:
Consultant: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Lilly, Merck, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Pathology’s (ABPath) Continuing Certification program and earn up to 1.0 CC points. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting Continuing Certification credit within approximately 30 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release, March 31, 2022, to March 30, 2023.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABPath CC Point(s)
Released: March 31, 2022
Expires: March 30, 2023
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other health care professionals involved in the management of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the role of trophoblast cell surface antigen 2 (TROP2) in tumor biology as well as its implications as a cancer biomarker.
  • Describe how novel antibody drug conjugates exploit TROP2 as an anticancer therapy.
  • Examine current unmet needs for patients with NSCLC without actionable mutations.
  • Assess the latest clinical safety and efficacy regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior treatment.

Activity Description

For patients with non-small cell lung cancer (NSCLC) who do not have actionable genomic alterations, programmed death ligand 1 immunotherapy, with or without platinum-based chemotherapy, is the standard of care. These regimens have demonstrated clear clinical benefit, yet 40% to 60% of patients do not respond to these initial therapies, or eventually experience disease progression. Options are limited for these patients, but novel therapies, such as antibody drug conjugates that target trophoblast cell surface antigen 2 (TROP2), are currently under clinical investigation. TROP2 is expressed in approximately 70% of NSCLC tumors, and expression has been associated with poor outcomes. In this continuing medical education activity, experts in the field will review current unmet needs for patients with NSCLC without actionable mutations, discuss the role of TROP2 in tumor biology and its implications as a cancer biomarker, and assess the most recent clinical safety and efficacy data regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior therapies.

Topic

  • Introduction
  • TROP2: Role in Tumor Biology and Implications for Biomarker (Jacob Sands, MD)
  • Second-line Therapy for Patients With Non-Small Cell Lung Cancer: Unmet Needs (Benjamin P. Levy, MD)
  • Advances in TROP2-Targeted Therapies for Patients With Non-Small Cell Lung Cancer (Rebecca Heist, MD)
  • Conclusion by Activity Chair

Activity Chair

Jacob Sands, MD
Physician, Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Boston, MA

Disclosure:
Consultant: AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Takeda

Faculty

Rebecca Heist, MD
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA

Disclosure:
Consultant: AbbVie, Daichii Sankyo, EMD Serono, Novartis
Independent Research Contractor (paid to institution): AbbVie, Agios, Corvus, Daichii Sankyo, Exelixis, Lilly, Mirati, Novartis, Turning Point


Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Washington, DC

Disclosure:
Consultant: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Lilly, Merck, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Pathology’s (ABPath) Continuing Certification program and earn up to 1.0 CC points. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting Continuing Certification credit within approximately 30 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release, March 31, 2022, to March 30, 2023.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Kevin R. Flaherty, MD, MS
0.25 CME
Vindico Medical Education
Clinical Presentation and Identification of CF-ILD: Journey to a Diagnosis of IPF

Clinical Presentation and Identification of CF-ILD: Journey to a Diagnosis of IPF

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
  • Evaluate optimal treatment strategies for patients with CF-ILD.

Activity Description

In this educational video, Drs. Kevin Flaherty and Marilyn Glassberg discuss the workup and clinical course of a patient with idiopathic pulmonary fibrosis.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Marilyn Glassberg, MD
Scientific Advisory Committee
Division Chief, Pulmonary Medicine, Critical Care and Sleep Medicine
University of Arizona College of Medicine
Phoenix, AZ

Relevant Disclosures:
Advisor: Bellerophon Therapeutics
Consultant: Genentech/Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
  • Evaluate optimal treatment strategies for patients with CF-ILD.

Activity Description

In this educational video, Drs. Kevin Flaherty and Marilyn Glassberg discuss the workup and clinical course of a patient with idiopathic pulmonary fibrosis.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Marilyn Glassberg, MD
Scientific Advisory Committee
Division Chief, Pulmonary Medicine, Critical Care and Sleep Medicine
University of Arizona College of Medicine
Phoenix, AZ

Relevant Disclosures:
Advisor: Bellerophon Therapeutics
Consultant: Genentech/Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Lisa H. Lancaster, MD
0.25 CME
Vindico Medical Education
Choosing the Optimal Treatment in a Patient With Progressive Fibrosing ILD

Choosing the Optimal Treatment in a Patient With Progressive Fibrosing ILD

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
  • Evaluate optimal treatment strategies for patients with CF-ILD.
  • Review up-to-date clinical data for the management of patients with CF-ILD in the era of COVID-19.

Activity Description

In this educational video, Drs. Kevin Flaherty and Lisa Lancaster discuss the assessment and management of a patient with chronic hypersensitivity pneumonitis.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Lisa H. Lancaster, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Relevant Disclosures:
Advisor: Bellerophon, United Therapeutics
Consultant: Bellerophon, Genentech, United Therapeutics
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, Genentech
Independent Research Contractor (paid to institution): Boehringer Ingelheim, Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
  • Evaluate optimal treatment strategies for patients with CF-ILD.
  • Review up-to-date clinical data for the management of patients with CF-ILD in the era of COVID-19.

Activity Description

In this educational video, Drs. Kevin Flaherty and Lisa Lancaster discuss the assessment and management of a patient with chronic hypersensitivity pneumonitis.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Lisa H. Lancaster, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Relevant Disclosures:
Advisor: Bellerophon, United Therapeutics
Consultant: Bellerophon, Genentech, United Therapeutics
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, Genentech
Independent Research Contractor (paid to institution): Boehringer Ingelheim, Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Lisa H. Lancaster, MD
0.25 CME
Vindico Medical Education
Managing Rheumatoid Arthritis-Associated ILD

Managing Rheumatoid Arthritis-Associated ILD

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Evaluate optimal treatment strategies for patients with CF-ILD.
  • Review up-to-date clinical data for the management of patients with CF-ILD in the era of COVID-19.
  • Examine the rationale for monitoring lung involvement in patients with diseases associated with CF-ILD.

Activity Description

In this educational video, Drs. Lisa Lancaster and Kevin Flaherty review the case of a patient with rheumatoid arthritis-associated interstitial lung disease.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Lisa H. Lancaster, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Relevant Disclosures:
Advisor: Bellerophon, United Therapeutics
Consultant: Bellerophon, Genentech, United Therapeutics
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, Genentech
Independent Research Contractor (paid to institution): Boehringer Ingelheim, Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Evaluate optimal treatment strategies for patients with CF-ILD.
  • Review up-to-date clinical data for the management of patients with CF-ILD in the era of COVID-19.
  • Examine the rationale for monitoring lung involvement in patients with diseases associated with CF-ILD.

Activity Description

In this educational video, Drs. Lisa Lancaster and Kevin Flaherty review the case of a patient with rheumatoid arthritis-associated interstitial lung disease.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Lisa H. Lancaster, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Relevant Disclosures:
Advisor: Bellerophon, United Therapeutics
Consultant: Bellerophon, Genentech, United Therapeutics
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, Genentech
Independent Research Contractor (paid to institution): Boehringer Ingelheim, Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Roy S. Herbst, MD, PhD
0.75 CME / MOC
RMEI Medical Education, LLC
On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.